Join the Comtan group to help and get support from people like you.
Comtan News
FDA Medwatch Alert: FDA Review Finds No Increased Risk of Prostate Cancer with Parkinson's Disease Medicines Containing Entacapone (Comtan, Stalevo)
August 13, 2019 – A U.S. Food and Drug Administration (FDA) review of additional data found no increased risk of prostate cancer with the use of entacapone to treat Parkinson’s disease. We conducted ...
FDA Medwatch Alert: Entacapone: Drug Safety Communication - FDA Review Found No Increased Cardiovascular Risks
Including Comtan (entacapone) and Stalevo (entacapone, carbidopa, and levodopa) ISSUE: An FDA safety review has found no clear evidence of an increased risk of heart attacks, stroke, or other...
Ask a question
To post your own question to this support group, sign in or create an account.